TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Down 56.0% in June

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 448,500 shares, a drop of 56.0% from the May 31st total of 1,020,000 shares. Approximately 6.9% of the shares of the stock are sold short. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

TransCode Therapeutics Trading Down 0.5 %

Shares of RNAZ traded down $0.01 during mid-day trading on Friday, reaching $1.01. 217,557 shares of the company’s stock were exchanged, compared to its average volume of 983,637. The company has a 50-day simple moving average of $1.09 and a two-hundred day simple moving average of $1.84. TransCode Therapeutics has a 52-week low of $0.42 and a 52-week high of $128.00.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of TransCode Therapeutics in a research report on Wednesday, May 29th.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.